AMINOPHYLLINE DYE FREE Drug Patent Profile
✉ Email this page to a colleague
When do Aminophylline Dye Free patents expire, and when can generic versions of Aminophylline Dye Free launch?
Aminophylline Dye Free is a drug marketed by Actavis Mid Atlantic and is included in one NDA.
The generic ingredient in AMINOPHYLLINE DYE FREE is aminophylline. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aminophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aminophylline Dye Free
A generic version of AMINOPHYLLINE DYE FREE was approved as aminophylline by HOSPIRA on October 26th, 1983.
Summary for AMINOPHYLLINE DYE FREE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Clinical Trials: | 36 |
| Patent Applications: | 5,498 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | AMINOPHYLLINE DYE FREE at DailyMed |
Recent Clinical Trials for AMINOPHYLLINE DYE FREE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 1/Phase 2 |
| University of Oklahoma | Phase 1/Phase 2 |
| Institute of Liver and Biliary Sciences, India | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for AMINOPHYLLINE DYE FREE
US Patents and Regulatory Information for AMINOPHYLLINE DYE FREE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | AMINOPHYLLINE DYE FREE | aminophylline | SOLUTION;ORAL | 087727-001 | Apr 16, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
